Drugs / CBS-9106
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | 2015-12-24 | “昨日、SL-801の米国FDAへの臨床試験開始申請（IND申請）が完了したと発表がありました。” canbas.co.jp ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02667873 | Feb 2016 → Oct 2021 | cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-09-12 | CanBas Co. Ltd. | Results CBS9106（SL-801）臨床第1相試験途中経過への所感 canbas.co.jp ↗
今回のStemlineのポスター発表で報告されたとおり、CBS9106（SL-801）は第6コホート（40mg/日）まで用量の漸増が進められています。 |
| 2015-12-24 | CanBas Co. Ltd. | Regulatory Stemline社によるIND申請完了の発表を受けて canbas.co.jp ↗
昨年末当社のCBS9106（先方の呼び方はSL-801です）を導出したStemline社から、昨日、SL-801の米国FDAへの臨床試験開始申請（IND申請）が完了したと発表がありました。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-08-05 | CanBas Co. Ltd. | CBS9106/SL-801 続報 canbas.co.jp ↗ |
| 2017-09-12 | CanBas Co. Ltd. | CBS9106（SL-801）臨床第1相試験途中経過への所感 canbas.co.jp ↗ |
| 2015-12-24 | CanBas Co. Ltd. | Stemline社によるIND申請完了の発表を受けて canbas.co.jp ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBS-9106 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298104 ↗ |
| Known as | Felezonexor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298104 ↗ |
| Known as | S-03747 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298104 ↗ |
| Known as | SL-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02667873 ↗ |
| Action | Inhibit | “SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).” NCT02667873 ↗ |
| Modality | Small molecule | “SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).” NCT02667873 ↗ |
| Route | Oral | “SL-801 will be administered orally” NCT02667873 ↗ |
| Target | XPO1 | “nuclear export protein Exportin-1 (XPO1)” NCT02667873 ↗ |